Conclusion The combination regimen of HHT and Ara cis effective and economical in patient with late chronic-phasechronic myelogenous leukemia(CML).
结论高三尖杉酯碱联合低剂量阿糖胞苷治疗慢粒白血病急变简便，经济，有效。
2
A team of researchers from the U. s. and Europe, including the drug's creator, Brian Druker, MD, followed 454 patients with chronic-phase CML taking imatinib for more than six years.
In its second phase the company had positive results when testing their device for chronic rhinosinusitis with polyposis, chronic rhinosinusitis without polyposis and migraine therapies.